CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway.
Nunzio Del Gaudio, Antonella Di Costanzo, Ning Qing Liu, Lidio Conte, Carmela Dell'Aversana, Guglielmo Bove, Rosaria Benedetti, Liliana Montella, Fortunato Ciardiello, Vincenzo Carafa, Concetta Ambrosino, Valeria Tucci, Mariarosaria Conte, Joost H A Martens, Hendrik G Stunnenberg, Angela Nebbioso, Lucia Altucci
Molecular cancer 2022 Jun 09The dynamic epigenome and proteins specialized in the interpretation of epigenetic marks critically contribute to leukemic pathogenesis but also offer alternative therapeutic avenues. Targeting newly discovered chromatin readers involved in leukemogenesis may thus provide new anticancer strategies. Accumulating evidence suggests that the PRC1 complex member CBX2 is overexpressed in solid tumors and promotes cancer cell survival. However, its role in leukemia is still unclear. We exploited reverse genetic approaches to investigate the role of CBX2 in human leukemic cell lines and ex vivo samples. We also analyzed phenotypic effects following CBX2 silencing using cellular and molecular assays and related functional mechanisms by ATAC-seq and RNA-seq. We then performed bioinformatic analysis of ChIP-seq data to explore the influence of histone modifications in CBX2-mediated open chromatin sites. Lastly, we used molecular assays to determine the contribution of CBX2-regulated pathways to leukemic phenotype. We found CBX2 overexpressed in leukemia both in vitro and ex vivo samples compared to CD34+ cells. Decreased CBX2 RNA levels prompted a robust reduction in cell proliferation and induction of apoptosis. Similarly, sensitivity to CBX2 silencing was observed in primary acute myeloid leukemia samples. CBX2 suppression increased genome-wide chromatin accessibility followed by alteration of leukemic cell transcriptional programs, resulting in enrichment of cell death pathways and downregulation of survival genes. Intriguingly, CBX2 silencing induced epigenetic reprogramming at p38 MAPK-associated regulatory sites with consequent deregulation of gene expression. Our results identify CBX2 as a crucial player in leukemia progression and highlight a potential druggable CBX2-p38 MAPK network in AML. © 2022. The Author(s).
Citation
Nunzio Del Gaudio, Antonella Di Costanzo, Ning Qing Liu, Lidio Conte, Carmela Dell'Aversana, Guglielmo Bove, Rosaria Benedetti, Liliana Montella, Fortunato Ciardiello, Vincenzo Carafa, Concetta Ambrosino, Valeria Tucci, Mariarosaria Conte, Joost H A Martens, Hendrik G Stunnenberg, Angela Nebbioso, Lucia Altucci. CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway. Molecular cancer. 2022 Jun 09;21(1):125
Mesh Tags
Substances
PMID: 35681235
View Full Text
